Clinical Trials Browser

Phase 1/2 × NIH × Decitabine × Clear all

NCT05918055 2025-12-02

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Phase 1/2 Terminated

3 enrolled 9 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05148234 2025-09-30

BMS-986253 in Myelodysplastic Syndromes

Phase 1/2 Terminated

2 enrolled 11 charts

Classical hematologyMyeloid

Cytopenia, Myelodysplastic Syndromes

NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Phase 1/2 Terminated

9 enrolled 14 charts

GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

NCT02996474 2022-12-28

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Phase 1/2 Completed

10 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute